Read more about the exciting work that has earned the Segal Lab $1.1 Million for research.
RDr. Dindot’s 3 goals, which have been the focus of his AS research through the FIRE initiative, are;
Mechanisms regulating imprinting of UBE3A in neurons, Identification of new therapeutic potentials for AS using high
throughput assays and Generation of new animal models of AS.
Ketone ester supplementation attenuates seizure activity, and improves behavior and hippocampal synaptic plasticity in an Angelman syndrome mouse model
Dr Allyson Berent, the Chief Science Officer at the Foundation for Angelman Syndrome Therapeutics, talks with popular radio journalist Maggie Linton about Angelman Syndrome awareness and the future therapeutics and clinical trials on Sirius XM Urban View.